ArticleJACC. Advances2026
Temporal Trends in Transcatheter Tricuspid Valve Interventions After FDA Approval in the United States.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter tricuspid valve interventions (TTVIs) have recently received commercial approval; however, contemporary adoption trends in early postapproval phase are not well described.
objectivesThe objectives of the study were to characterize trends in utilization of transcatheter tricuspid edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) and to describe baseline patient characteristics and in-hospital outcomes.
methodsWe performed a retrospective cohort study using the Vizient Clinical Data Base including patients who underwent T-TEER or TTVR between October 2024 and December 2025. Monthly procedural trends, baseline characteristics, and in-hospital outcomes were evaluated.
resultsThe study included 2,143 T-TEER procedures performed at 180 implanting hospitals; median annualized hospital volume 6.4 (IQR: 2.4-13.6) and 1,301 TTVR procedures performed at 113 implanting hospitals; median annualized hospital volume 6.4 (IQR: 3.2-11.2). Overall monthly volumes increased for both T-TEER (128 in October 2024 to 156 in December 2025; P for trend = 0.004) and TTVR (60 in October 2024 to 111 in December 2025; P for trend <0.001). The proportion of TTVR among all TTVI increased over time (from 31.9% to 41.6%; P for trend = 0.006). Baseline patient comorbidities of patients undergoing TTVI were similar to pivotal trial populations. In-hospital mortality was 0.5% following T-TEER and 2.0% following TTVR. The incidence of major bleeding was 6.0% and 12.4% after T-TEER and TTVR, respectively. Among TTVR patients, 11.3% required new pacemaker implantation.
conclusionsThere is increased adoption of both T-TEER and TTVR in early commercial experience with clinical characteristics of treated patients similar to those enrolled in pivotal trials. In-hospital outcomes were overall favorable supporting the generalizability of the pivotal trial findings to contemporary practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.